论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
以掌跖脓疱病为首发表现的 SAPHO 综合征阿达木单抗成功治疗
Authors Yang Q, Xiang T, Wu Y, Ye E, He B, Bu Z
Received 30 July 2022
Accepted for publication 17 November 2022
Published 28 November 2022 Volume 2022:15 Pages 2547—2554
DOI https://doi.org/10.2147/CCID.S384346
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Jeffrey Weinberg
Introduction: Synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome is an acronym for synovitis, pustulosis, acne, hyperostosis, and osteitis, and clinically manifests as dermatological and musculoskeletal damage. Two major manifestations that co-occur in a single patient are rare.
Methods/Results: This literature describes a 44-year-old male affected by SAPHO syndrome, whose first manifestation was palmoplantar pustulosis (PPP). Symptomatic treatments such as anti-inflammatory and analgesics did not work well for him. Adalimumab provided noteworthy improvement in the neck and thoracic back pain improvement after two weeks. The palmoplantar pustules were alleviated after four weeks.
Conclusion: The literature on SAPHO syndrome therapy is increasing. Thus, adalimumab is a novel therapeutic agent. This report demonstrates the efficiency of adalimumab in SAPHO syndrome.
Keywords: synovitis, acne, psoriasis, bone hypertrophy, osteitis, psoriasis arthritis, adalimumab